New drug combo for advanced breast cancer shows promise but trial halted early
Disease control
Terminated
This phase 2 study tested a new drug called lerociclib combined with standard hormone therapy in 100 people with advanced HR+/HER2- breast cancer. The goal was to see if the combination is safe and effective. However, the trial was terminated early, so the full results are not av…
Phase: PHASE2 • Sponsor: EQRx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC